record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
accepted
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundobservational · manual state transition · Homo sapiens
proof impact
packet context2 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
observational
species
Homo sapiens
evidence spans
CLARITY-AD lecanemab eligibility required APOE genotyping with specific dosing protocols for APOE4 homozygotes after early ARIA-E rates exceeded 25% in that subgroup; bapineuzumab APOE4 ARIA-E precedent informed design.
Cascade-densification deposit: Bapineuzumab Phase III ARIA-E in APOE4 → APOE4-stratified eligibility adoption · curator_source · Cascade-densification deposit: Bapineuzumab Phase III ARIA-E in APOE4 → APOE4-stratified eligibility adoption
conditions
Provenance
source title
Cascade-densification deposit: Bapineuzumab Phase III ARIA-E in APOE4 → APOE4-stratified eligibility adoption
authors
reviewer:will-blair-bot
CLARITY-AD lecanemab eligibility required APOE genotyping with specific dosing protocols for APOE4 homozygotes after early ARIA-E rates exceeded 25% in that subgroup; bapineuzumab APOE4 ARIA-E precedent informed design.
vs_afe1fae94e7b014e · source:Cascade-densification deposit: Bapineuzumab Phase III ARIA-E in APOE4 → APOE4-stratified eligibility adoption|section:curator_source · manual_curation
outgoing
No outgoing links.
incoming
No incoming links.
events
vev_52ec2ccaad20968ffinding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_af2a9505e2363a04finding.reviewedAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_76a4ee28cc03caeffinding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_c52c545b2fae2cbcfinding.reviewAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation record targets this finding id.